NEW YORK (GenomeWeb News) — Sirius Genomics will collaborate with a UK research group focused on human disease gene studies to develop the company’s pharmacogenomic test for patient response to a drug treatment for infection and sepsis.
Sirius said today that the United Kingdom Critical Care Genomics Group will help develop its test for responsiveness to recombinant actived Protein C, which is marketed by Eli Lilly under the name Xigris.
"The UKCCG group is conducting a large genomic association study looking at severe life-threatening infections and sepsis,” Sirius Genomics CEO Brad Popovich said in a statement. He added that the collaboration will allow the company to “significantly advance the development of our diagnostic by accessing the comprehensive database that the UKCCG group has compiled.”
Financial terms of the agreement were not disclosed.